Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?

J Clin Oncol. 2010 Jul 20;28(21):3407-10. doi: 10.1200/JCO.2009.26.0125. Epub 2010 Jun 7.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Anthracyclines / administration & dosage*
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy
  • Chemotherapy, Adjuvant
  • Female
  • Heart Diseases / chemically induced*
  • Heart Failure / chemically induced
  • Humans
  • Receptor, ErbB-2 / analysis
  • Receptor, ErbB-2 / genetics
  • Trastuzumab
  • Ventricular Function, Left / drug effects

Substances

  • Anthracyclines
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab